Journal
BREAST
Volume 62, Issue -, Pages S70-S79Publisher
CHURCHILL LIVINGSTONE
DOI: 10.1016/j.breast.2021.12.008
Keywords
CDK4/6 inhibitors; Endocrine therapy; Hormone receptor positive breast cancer; Early setting
Categories
Funding
- St. Gallen Oncology Conferences
Ask authors/readers for more resources
CDK4/6 inhibitors have a proven role in the treatment of breast cancer, delaying disease progression and improving survival. However, there are discrepancies in the results between early breast cancer and metastatic breast cancer studies, which require further investigation for clarification.
CDK4/6 inhibitors have an established role in the treatment of hormone receptor positive HER2-negative advanced breast cancer. All studies conducted in metastatic breast cancer showed a benefit in delaying progression when added to standard endocrine therapy, regardless of therapy line, pretreatment, menopausal status, site of metastasis, CDK4/6 inhibitor used and associated endocrine therapy. A benefit in overall survival has also been demonstrated. In early breast cancer, only the MonarchE study has shown an improved invasive disease-free survival with abemaciclib taken for 2 years, whereas the Penelope-B did not meet the primary endpoint and the PALLAS study was terminated early for futility. Studies conducted in the neoadjuvant setting might help to explain the discordant results.(C) 2022 The Authors. Published by Elsevier Ltd.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available